In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.

The tool predicts which of two standard front-line chemotherapy options a patient with advanced pancreatic cancer is likely to benefit from.

Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.